Background: Lipoprotein(a) [Lp(a)] has enhanced atherothrombotic properties. Also, Lp(a) is known to be associated with cardiovascular complications of general populations. However, the ability of Lp(a) levels to predict adverse cardiovascular outcomes in patients (pts) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) has not been examined. Methods: The study population consisted of 1015 consecutive pts underwent PCI with DESs enrolled from 2004 to 2008. We subdivided the pts into 2 groups of plasma Lp(a) concentration: Lp(a) <50 (n=1215), and Lp(a)���50 mg/dl (n=241). 2-year cumulative major clinical outcomes were compared among two groups. Results: The baseline clinical characteristics including age, diabetes, hypertension, smoking, chronic kidney disease, left ventricular ejection fraction, myocardial infarction, number of coronary vessel disease were similar among two groups except gender, dyslipidemia, hemoglobin, and serum creatinine level (table). At 2-year follow-up (82.6%), major clinical outcomes including total major adverse cardiac events (MACE), target vessel revascularization (TLR), target lesion revascularization (TVR), TLR-MACE, TVR-MACE , and all death were higher in Lp(a)���50 mg/dl group (table). Also, Multivariate analysis adjusted by gender, dyslipidemia, Hemoglobin, and creatinine showed that total MACE, TLR-MACE, TVR-MACE, TLR, and TVR were significantly higher in Lp(a)���50 mg/dl group (table). Conclusions: In our study, Lp(a) level in pts undergoing PCI with DESs was closely associated with worse clinical outcomes up to 2 years.